CO2017011564A2 - Métodos y kits para tratar la depresión - Google Patents

Métodos y kits para tratar la depresión

Info

Publication number
CO2017011564A2
CO2017011564A2 CONC2017/0011564A CO2017011564A CO2017011564A2 CO 2017011564 A2 CO2017011564 A2 CO 2017011564A2 CO 2017011564 A CO2017011564 A CO 2017011564A CO 2017011564 A2 CO2017011564 A2 CO 2017011564A2
Authority
CO
Colombia
Prior art keywords
kits
methods
treatment
depression
treat depression
Prior art date
Application number
CONC2017/0011564A
Other languages
English (en)
Spanish (es)
Inventor
Ivo Caers
Ella Daly
Wayne C Drevets
Jaskaran Singh
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2017011564A2 publication Critical patent/CO2017011564A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CONC2017/0011564A 2015-05-20 2017-11-14 Métodos y kits para tratar la depresión CO2017011564A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
PCT/US2016/033404 WO2016187491A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression

Publications (1)

Publication Number Publication Date
CO2017011564A2 true CO2017011564A2 (es) 2018-04-19

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011564A CO2017011564A2 (es) 2015-05-20 2017-11-14 Métodos y kits para tratar la depresión

Country Status (20)

Country Link
US (1) US20160338977A1 (https=)
EP (1) EP3297618A4 (https=)
JP (1) JP2018515557A (https=)
KR (1) KR20180008634A (https=)
CN (1) CN107735081A (https=)
AU (3) AU2016263598A1 (https=)
CA (1) CA2986477A1 (https=)
CL (1) CL2017002904A1 (https=)
CO (1) CO2017011564A2 (https=)
DO (1) DOP2017000268A (https=)
EA (1) EA201792545A1 (https=)
EC (1) ECSP17077930A (https=)
GT (1) GT201700246A (https=)
HK (1) HK1252937A1 (https=)
IL (1) IL255463A (https=)
MA (1) MA42135A (https=)
MX (1) MX2017014797A (https=)
PE (1) PE20180260A1 (https=)
PH (1) PH12017502103A1 (https=)
WO (1) WO2016187491A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20240011237A (ko) * 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
BR112020023882A2 (pt) * 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN112702995A (zh) * 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2022524008A (ja) * 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ,インコーポレーテッド うつ病の治療のためのエスケタミン
CN114286674A (zh) * 2019-08-28 2022-04-05 杨森制药公司 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
JP7840873B2 (ja) * 2020-05-28 2026-04-06 ヤンセン ファーマシューティカ エヌ.ベー. うつ病の治療方法
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP2830604A4 (en) * 2012-03-30 2015-08-19 Gen Hospital Corp COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
DK2983787T3 (da) * 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Fremgangsmåde til behandling af posttraumatisk stresssygdom
AU2015318123A1 (en) * 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression

Also Published As

Publication number Publication date
AU2016263598A1 (en) 2017-11-23
GT201700246A (es) 2019-07-29
CL2017002904A1 (es) 2018-04-20
IL255463A (en) 2018-01-31
KR20180008634A (ko) 2018-01-24
JP2018515557A (ja) 2018-06-14
EA201792545A1 (ru) 2018-05-31
ECSP17077930A (es) 2018-02-28
PE20180260A1 (es) 2018-02-05
DOP2017000268A (es) 2018-04-15
US20160338977A1 (en) 2016-11-24
HK1252937A1 (zh) 2019-06-06
EP3297618A1 (en) 2018-03-28
PH12017502103A1 (en) 2018-05-07
AU2021215155A1 (en) 2021-09-02
CA2986477A1 (en) 2016-11-24
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
EP3297618A4 (en) 2019-01-23
WO2016187491A1 (en) 2016-11-24
MA42135A (fr) 2018-03-28
CN107735081A (zh) 2018-02-23
MX2017014797A (es) 2018-02-15

Similar Documents

Publication Publication Date Title
CO2017011564A2 (es) Métodos y kits para tratar la depresión
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
MX373187B (es) Terapia de combinación para tratar cáncer.
MX388325B (es) Metodos de diagnostico para tratamiento con linfocitos t.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX392752B (es) Terapia de combinacion para tratar cancer.
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).
CL2022001177A1 (es) Tregímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax.
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
AR105701A1 (es) Métodos y estuches para tratar la depresión
AR109858A1 (es) Métodos que usan inhibidores hdac11